Publisher
Springer International Publishing
Reference117 articles.
1. Sanz MA, Lo Coco F, Martín G, Avvisati G, Rayón C, Barbui T, et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood. 2000;96(4):1247–53.
2. Iland HJ, Seymour JF, Wei A. Optimal approach for high-risk acute promyelocytic leukemia. Curr Opin Hematol. 2014;21(2):102–13.
3. Sanz MA, Martin G, Lo Coco F. Choice of chemotherapy in induction, consolidation and maintenance in acute promyelocytic leukaemia. Baillieres Best Pract Res Clin Haematol. 2003;16(3):433–51.
4. Le Deley M-C, Leblanc T, Shamsaldin A, Raquin M-A, Lacour B, Sommelet D, et al. Risk of secondary leukemia after a solid tumor in childhood according to the dose of Epipodophyllotoxins and Anthracyclines: a case-control study by the Société Française d’Oncologie Pédiatrique. J Clin Oncol. 2003;21(6):1074–81.
5. Praga C, Bergh J, Bliss J, Bonneterre J, Cesana B, Coombes RC, et al. Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide. J Clin Oncol. 2005;23(18):4179–91.